242 related articles for article (PubMed ID: 22748604)
1. Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Rosenbaum D; Dallongeville J; Sabouret P; Bruckert E
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):871-5. PubMed ID: 22748604
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
[TBL] [Abstract][Full Text] [Related]
3. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
5. [Statin therapy and muscle disorders].
Abel T; Fehér J
Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
[No Abstract] [Full Text] [Related]
6. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Mori Y; Kuriyama G; Tanaka T; Tajima N
Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827
[No Abstract] [Full Text] [Related]
9. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
11. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
Golightly LK; Barber GR; Barron MA; Page RL
Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
[TBL] [Abstract][Full Text] [Related]
13. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
15. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
16. Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
Ann Intern Med; 2014 Mar; 160(5):I-34. PubMed ID: 24737270
[No Abstract] [Full Text] [Related]
17. Safety of rosuvastatin.
Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
[TBL] [Abstract][Full Text] [Related]
18. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
Mohiuddin SM; Thakker KM; Setze CM; Kelly MT
Curr Med Res Opin; 2011 May; 27(5):1067-78. PubMed ID: 21438793
[TBL] [Abstract][Full Text] [Related]
19. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
Singh S; Nautiyal A; Dolan JG
JOP; 2004 Nov; 5(6):502-4. PubMed ID: 15536291
[TBL] [Abstract][Full Text] [Related]
20. New light on statin side effects. What recent research on the cholesterol drugs means to you.
Heart Advis; 2005 Aug; 8(8):3. PubMed ID: 16193557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
